The FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend adding BPC-157 to the 503A Bulk Drug Substances List represents the clearest recent catalyst for trader sentiment, overriding staff concerns over sparse human data, immunogenicity risks, and limited characterization for proposed routes such as oral, subcutaneous, or nasal use. That non-binding recommendation followed the peptide’s April 2026 removal from Category 2 after related nominations were withdrawn, shifting it from presumptive enforcement risk into a formal review track. Full movement to Category 1 status—enabling routine compounding under 503A—still requires FDA acceptance of the recommendation plus notice-and-comment rulemaking, a process that historically spans eight to twenty-four months. As of early September 2026, no proposed rule has been published and no final determination issued. Key variables that could accelerate or delay resolution include administration priorities on compounding access, the volume and content of public comments once rulemaking begins, and any new safety signals from adverse-event reporting.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วใหม่
Dec 31, 2026
December 31, 2026
54%
$4,143 ปริมาณ
December 31, 2026
$2,141 ปริมาณ
54%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend adding BPC-157 to the 503A Bulk Drug Substances List represents the clearest recent catalyst for trader sentiment, overriding staff concerns over sparse human data, immunogenicity risks, and limited characterization for proposed routes such as oral, subcutaneous, or nasal use. That non-binding recommendation followed the peptide’s April 2026 removal from Category 2 after related nominations were withdrawn, shifting it from presumptive enforcement risk into a formal review track. Full movement to Category 1 status—enabling routine compounding under 503A—still requires FDA acceptance of the recommendation plus notice-and-comment rulemaking, a process that historically spans eight to twenty-four months. As of early September 2026, no proposed rule has been published and no final determination issued. Key variables that could accelerate or delay resolution include administration priorities on compounding access, the volume and content of public comments once rulemaking begins, and any new safety signals from adverse-event reporting.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Jun 22, 2026, 10:10 PM ET
ปริมาณการซื้อขาย
$4,143วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Jun 22, 2026, 10:10 PM ETผู้ตัดสินผล
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend adding BPC-157 to the 503A Bulk Drug Substances List represents the clearest recent catalyst for trader sentiment, overriding staff concerns over sparse human data, immunogenicity risks, and limited characterization for proposed routes such as oral, subcutaneous, or nasal use. That non-binding recommendation followed the peptide’s April 2026 removal from Category 2 after related nominations were withdrawn, shifting it from presumptive enforcement risk into a formal review track. Full movement to Category 1 status—enabling routine compounding under 503A—still requires FDA acceptance of the recommendation plus notice-and-comment rulemaking, a process that historically spans eight to twenty-four months. As of early September 2026, no proposed rule has been published and no final determination issued. Key variables that could accelerate or delay resolution include administration priorities on compounding access, the volume and content of public comments once rulemaking begins, and any new safety signals from adverse-event reporting.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$4,143วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Jun 22, 2026, 10:10 PM ETผู้ตัดสินผล
0x65070BE91...The FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend adding BPC-157 to the 503A Bulk Drug Substances List represents the clearest recent catalyst for trader sentiment, overriding staff concerns over sparse human data, immunogenicity risks, and limited characterization for proposed routes such as oral, subcutaneous, or nasal use. That non-binding recommendation followed the peptide’s April 2026 removal from Category 2 after related nominations were withdrawn, shifting it from presumptive enforcement risk into a formal review track. Full movement to Category 1 status—enabling routine compounding under 503A—still requires FDA acceptance of the recommendation plus notice-and-comment rulemaking, a process that historically spans eight to twenty-four months. As of early September 2026, no proposed rule has been published and no final determination issued. Key variables that could accelerate or delay resolution include administration priorities on compounding access, the volume and content of public comments once rulemaking begins, and any new safety signals from adverse-event reporting.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย